leadf
logo-loader
viewDirecta Plus PLC

Directa Plus PLC - Setcar Update

RNS Number : 9856B
Directa Plus PLC
14 October 2020
 

14 October 2020

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Setcar update

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to provide an update on the integration and current trading of Setcar SA ("Setcar"), the Company's 51%-owned environmental remediation business acquired in November 2019.

 

In the 10 months following the acquisition of Setcar, the business is delivering significantly improved results compared to previous years, despite the headwinds caused by the Covid-19 pandemic.

 

Highlights

·   Sales for the period 1 January 2020 to 1 October 2020 increased to €3.0m (equivalent previous period: €2.6m)

·   132 new contracts have been signed since 1 January 2020

·   Since the start of 2020, Setcar has participated in 77 tenders for new business, of which 32 were awarded to Setcar, with a further 9 still under evaluation by the potential customers

·   Contracted order book is expected to generate revenue of €4.0m during 2021 and €3.0m during 2022

·   Post-acquisition integration continues to progress well and the Company continues to invest to reshape the Setcar business to ensure better growth opportunities.

 

Giulio Cesareo, Chief Executive of Directa Plus, added: "We are delighted with the performance of Setcar. Since acquiring the company, our strategy has been to capture new high potential business opportunities leveraging on our patented Grafysorber® technology and we are now working to expand Setcar's product offer with the addition of our other G+ products.

 

This success is a reflection of the growing strength of Directa Plus in the Environmental vertical.

The outstanding work of Setcar's team, led by our COO, Razvan Popescu, has delivered these excellent results even in the current global economic situation.

 

The foundations for further growth in the coming few years are clearly laid, and we look forward to growing with Setcar."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Marco Ferrari, CFO

 

 

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Pete Lynch

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Rick Thompson

Phil Davies

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products).  In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products.  All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAEEDFLFEFAA

Quick facts: Directa Plus PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE jumps on AstraZeneca COVID-19 vaccine trial and easing...

FTSE 100 rallied in early trading on AstraZeneca’s COVID-19 vaccine trial and the easing of lockdown restrictions from December. London’s blue-chip index rose 20 to 6,371. AstraZeneca PLC (LON:AZN) announced that the coronavirus (COVID-19) vaccine it has developed with Oxford University was...

4 days, 6 hours ago

4 min read